Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This is a study evaluating the safety and effectiveness of Combretastatin A4 Phosphate (CA4P)
combined with the chemotherapy drugs, carboplatin and paclitaxel. The full treatment and
observation time should be about 5 months. During this time the patient should receive 18
CA4P infusions and 6 carboplatin followed by paclitaxel treatments. Patients will be
randomized into one of two CA4P dose-level groups in order to recommend a preferred
dose-level for future studies. At least 2 dynamic contrast enhanced-magnetic resonance
imaging (DCE-MRI) scans will be conducted to monitor the blood flow through the tumor before
and after treatment with CA4P.